Post-transplantation Cyclophosphamide (Cy) as a single agent for GVHD prophylaxis after HLA matched related and unrelated bone marrow transplantation

Abstract

In animal models of BMT, a properly timed high dose of Cy post-BMT selectively eliminates host-versus-graft and graft-versus-host reactive T cells, thereby preventing graft rejection and reducing GVHD. We hypothesized that high dose posttransplant Cy (50 mg/kg IV) administered on days +3 and +4 after BuCy conditioning may be effective in preventing GVHD and can limit, or entirely eliminate the need for, standard postgrafting immunosuppression. This should lessen immunosuppression and allow early institution of additional posttransplant immunotherapy such as DLI.